, Volume 196, Issue 5, pp 583–590 | Cite as

N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) as a Diagnostic Biomarker of Left Ventricular Systolic Dysfunction in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

  • Ilija Andrijevic
  • Senka Milutinov
  • Zagorka Lozanov Crvenkovic
  • Jovan Matijasevic
  • Ana Andrijevic
  • Tomi Kovacevic
  • Darijo Bokan
  • Bojan ZaricEmail author



Left ventricular systolic dysfunction (LVSD) and cardiac decompensation often accompany AECOPD. Differentiation between the two is difficult and mainly relies on clinical and echocardiographic diagnostic procedures. The value of biomarkers, such as NT-proBNP, as diagnostic tools is still insufficiently investigated. The main goals of this trial were to investigate the value of NT-proBNP as a diagnostic tool for LVSD in AECOPD patients and determine its cut-off value which could reliably diagnose LVSD during AECOPD.

Patients and Methods

This trial prospectively enrolled 209 patients with AECOPD. The patients were divided into four groups—AECOPD plus chronic pulmonary heart disease (CPHD) with or without left ventricular compromise (LVSD), and AECOPD patients without CPHD with or without LVSD. NT-proBNP was measured within first 48 h of hospitalization.


Majority of patients were male (61%) active smokers (41.6%), average age of 68 years. High quality of echocardiography was obtained in 63.3 and 22.5% of the patients had LVSD. Average value of NT-proBNP in patients with LVSD was 3303.2 vs. 1092.5 pg/mL in patients without LVSD. Significant differences in NT-proBNP value (p = 0.0001) were determined between observed patient groups. At the cut-off value of 1505 pg/mL, sensitivity, specificity, and positive and negative predictive values are 76.6, 83.3, 57.1, and 92.47%, respectively.


At the cut-off value of 1505 pg/mL NT-proBNP could be used as a diagnostic marker for LVSD in acute exacerbation of COPD.


Acute exacerbation Chronic obstructive pulmonary disease (COPD) Left ventricular dysfunction (LVD) NT-proBNP 


Compliance with Ethical Standards

Conflict of interest

The authors declare they have no conflict of interest related to the present manuscript.

Ethical Approval

This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

408_2018_137_MOESM1_ESM.docx (16 kb)
Supplementary material 1 (DOCX 16 KB)


  1. 1.
    Patel AR, Kowlessar BS, Donaldson GC, Mackay AJ, Singh R, George SN et al (2013) Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 188(9):1091–1099CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Marcun R, Stankovic I, Vidakovic R, Farkas J, Kadivec S, Putnikovic B et al (2016) Prognostic implications of heart failure with preserved ejection fraction in patients with an exacerbation of chronic obstructive pulmonary disease. Intern Emerg Med 11(4):519–527CrossRefPubMedGoogle Scholar
  3. 3.
    Calzetta L, Orlandi A, Page C, Rogliani P, Rinaldi B, Rosano G (2016) Brain natriuretic peptide: much more than a biomarker. Int J Cardiol 221:1031–1038CrossRefPubMedGoogle Scholar
  4. 4.
    Buchan A, Bennett R, Coad A, Barnes S, Russell R, Manuel AR (2015) The role of cardiac biomarkers for predicting left ventricular dysfunction and cardiovascular mortality in acute exacerbations of COPD. Open Heart 2(1):e000052CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lomholt FK, Laulund AS, Bjarnason NH, Jørgensen HL, Godtfredsen NS (2014) Meta-analysis of routine blood tests as predictors of mortality in COPD. Eur Clin Respir J. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Koskela HO, Salonen PH, Romppanen J, Hartikainen J (2015) Plasma amino-terminal pro B-type natriuretic peptide as a predictor of late cardiovascular mortality in patients with acute lung disorders: a prospective, observational cohort study. ESC Heart Fail 2(2):69–75CrossRefPubMedGoogle Scholar
  7. 7.
    Høiseth AD, Omland T, Hagve TA, Brekke PH, Søyseth V (2012) NT-proBNP independently predicts long term mortality after acute exacerbation of COPD—a prospective cohort study. Respir Res 13:97CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Medina AM, Marteles MS, Sáiz EB, Martínez SS, Laiglesia FR, Rodríguez JA et al (2011) Prognostic utility of NT-proBNP in acute exacerbations of chronic pulmonary diseases. Eur J Intern Med 22(2):167–171CrossRefPubMedGoogle Scholar
  9. 9.
    Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD et al (2011) Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 66(9):764–768CrossRefPubMedGoogle Scholar
  10. 10.
    Lee MH, Chang CL, Davies AR, Davis M, Hancox RJ (2013) Cardiac dysfunction and N-terminal pro-B-type natriuretic peptide in exacerbations of chronic obstructive pulmonary disease. Intern Med J 43(5):595–598CrossRefPubMedGoogle Scholar
  11. 11.
    Huang YS, Feng YC, Zhang J, Bai L, Huang W, Li M et al (2014) Impact of chronic obstructive pulmonary diseases on left ventricular diastolic function in hospitalized elderly patients. Clin Interv Aging 10:81–87PubMedPubMedCentralGoogle Scholar
  12. 12.
    Chi SY, Kim EY, Ban HJ, Oh IJ, Kwon YS, Kim KS,et al (2012) Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease. Lung 190(3):271–276CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Rubinsztajn R, Nasiłowski J, Przybyłowski T, Karwat K, Chazan R (2013) Usefulness of NT-proBNP serum level in the diagnosis of dyspnea in COPD patients. Pneumonol Alergol Pol 81(1):24–29PubMedGoogle Scholar
  14. 14.
    Wang QP, Cao XZ, Wang XD, Gu J, Wen LM, Mao LM et al (2013) Utility of NT-proBNP for identifying LV failure in patients with acute exacerbation of chronic bronchitis. PLoS ONE 8(1):e52553CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ouanes I, Jalloul F, Ayed S, Dachraoui F, Ouanes-Besbes L, Fekih Hassen M et al (2012) N-terminal proB-type natriuretic peptide levels aid the diagnosis of left ventricular dysfunction in patients with severe acute exacerbations of chronic obstructive pulmonary disease and renal dysfunction. Respirology 17(4):660–666CrossRefPubMedGoogle Scholar
  16. 16.
    Prosen G, Klemen P, Štrnad M, Grmec S (2011) Combination of lung ultrasound (a comet-tail sign) and N-terminal pro-brain natriuretic peptide in differentiating acute heart failure from chronic obstructive pulmonary disease and asthma as cause of acute dyspnea in prehospital emergency setting. Crit Care 15(2):R114CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tung RH, Camargo CA Jr, Krauser D, Anwaruddin S, Baggish A, Chen A et al (2006) Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann Emerg Med 48(1):66–74CrossRefPubMedGoogle Scholar
  18. 18.
    Klemen P, Golub M, Grmec S (2009) Combination of quantitative capnometry, N-terminal pro-brain natriuretic peptide, and clinical assessment in differentiating acute heart failure from pulmonary disease as cause of acute dyspnea in pre-hospital emergency setting: study of diagnostic accuracy. Croat Med J 50(2):133–142CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Abroug F, Ouanes-Besbes L, Nciri N, Sellami N, Addad F et al (2006) Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 174(9):990–996CrossRefPubMedGoogle Scholar
  20. 20.
    Rutten FH, Cramer MJ, Zuithoff NP, Lammers JW, Verweij W, Grobbee DE et al (2007) Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail 9(6–7):651–659CrossRefPubMedGoogle Scholar
  21. 21.
    El Mallawany H, Mahmoud MI, Morsi TS, EL-Shiekh RM (2014) Role of N-terminal pro B-type natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease. Egypt J Chest Dis Tuberc 63(1):57–65CrossRefGoogle Scholar
  22. 22.
    McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53(17):1573–1619CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute for Pulmonary Diseases of Vojvodina, Faculty of MedicineUniversity of Novi SadSremska KamenicaSerbia
  2. 2.Faculty of SciencesUniversity of Novi SadSremska KamenicaSerbia

Personalised recommendations